Investigating the role of endoglin in pancreatic cancer
Official title: Tumor-intrinsic and paracrine roles of endoglin in pancreatic cancer
Funded at University of Arizona · NIH-10895427 · Data updated 2026-11-12
This study is looking at how a protein called endoglin affects pancreatic cancer cells, with the goal of finding new ways to improve treatment for patients battling this tough cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $357,480 |
| NIH project number | 5R01CA275036-02 |
| Project ID | NIH-10895427 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma.
✕Less likely to help
Patients with other types of cancer or those without pancreatic cancer may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer known for its early spread and resistance to treatment. The study aims to explore how endoglin, a protein involved in blood vessel formation, behaves in pancreatic cancer cells and its impact on tumor growth and drug delivery. By examining different forms of endoglin and their effects on the tumor environment, the researchers hope to uncover new therapeutic targets that could enhance treatment effectiveness for patients with PDAC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving patient outcomes.
How similar studies have gone: While the specific approach of targeting endoglin in pancreatic cancer is novel, similar strategies targeting angiogenesis have shown promise in other cancer types.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Lee, Nam Y — University of Arizona
- Study coordinator: Lee, Nam Y
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.